Drugs from Bugs: The Anti-Inflammatory Drugs of Tomorrow

昆虫药物：明天的抗炎药物

基本信息

批准号：
8124051
负责人：
ANDREW D ROBERTSON
金额：
$ 0.84万
依托单位：
KEYSTONE SYMPOSIA
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-03-01 至 2011-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8124051
关键词：
Academia Address Adopted Anti-Inflammatory Agents Anti-inflammatory Asthma Basic Science Clinic Clinical Clinical Trials Collaborations Development Discipline Disease Drug usage Environmental Risk Factor Evolution Fostering Future Generations Genes Genome Grant Health Healthcare Human Human Genome Immune Immune system Immunology Incidence Industry Inflammatory Inflammatory Bowel Diseases Knowledge Laboratories Location Magic Mediating Mentors Methodology Outcome Patients Pharmaceutical Preparations Request for Proposals Research Research Personnel Scientist Staging Stream Technology Therapeutic Training Utah Viral Work career clinical practice drug development drug discovery expectation improved insight man meetings novel novel strategies novel therapeutics pathogen pressure research and development success symposium therapeutic development trend

项目摘要

DESCRIPTION (provided by applicant): This proposal requests support for a Keystone Symposia meeting entitled Drugs from Bugs: The Anti- Inflammatory Drugs of Tomorrow, organized by Padraic G. Fallon, Grant McFadden and Amanda E.I. Proudfoot Fichard, which will be held in Snowbird, Utah from April 3 - 7, 2011. A recent global trend is that fewer novel therapeutics are progressing from the pipeline to the clinic. This has prompted the drug research and development sector to adopt less conventional approaches in broadening the search for new drugs. The Keystone Symposia meeting on Drugs from Bugs: The Anti-Inflammatory Drugs of Tomorrow will examine the growing opportunities for discovery of novel drugs from pathogens, or the "drugs from bugs" approach. The genome of man is the product of the evolution of humans adapting to environmental factors, with infectious pathogens exerting potent selective pressure. Some of the major immune-mediated diseases of today are associated with genes that evolved to respond to pathogens. Novel therapeutic strategies and new drugs can be developed by both understanding how pathogens modulate and usurp the immune system, and also by identifying the functional molecules from pathogens. Indeed, a new generation of pathogen-derived immune modulating molecules is now in clinical trials. In this meeting leading experts will present the current status of the use of pathogens as a wellspring for new therapeutics. This forum will be an opportunity for industry to engage with academics for the development of novel strategies for drug discovery. This meeting will bring together cross-disciplinary scientists to exchange and share ideas, and thereby foster collaborations directed at the generation of new drug strategies for the future. Opportunities for interdisciplinary interactions will be significantly enhanced by the co-location of this meeting with the Keystone Symposia meeting on Evolving Approaches to Early-Stage Drug Discovery. PUBLIC HEALTH RELEVANCE: Advances in drug discovery technology have raised expectations that the global drug development industry will deliver "magic bullets" or "wonder drugs" for a range of diseases, in particular inflammatory disorders. In fact, fewer novel therapeutics are progressing from the pipeline to the clinic, and the lack of new treatments is a growing health concern due to the worldwide increase in the incidence of a range of many diseases, such as asthma and inflammatory bowel disease. The Keystone Symposia meeting on Drugs from Bugs: The Anti- Inflammatory Drugs of Tomorrow will examine the growing opportunities for discovery of novel drugs from pathogens, or the "drugs from bugs" approach.

描述（由申请人提供）：该提案要求支持Keystone研讨会会议的题为《臭虫的药物：明天的抗炎药》，由Padraic G. Fallon，Grant McFadden和Amanda E.I.组织。 Proudfoot Fichard将于2011年4月3日至7日在犹他州的雪鸟举行。最近的全球趋势是，从管道到诊所的新颖疗法越来越少。这促使药物研发部门采用较少传统的方法来扩大寻找新药的搜索。 Keystone研讨会会议上关于来自虫子的药物的会议：明天的抗炎药将研究从病原体中发现新型药物的日益增长的机会，或“虫子中的“药物”方法。人的基因组是人类适应环境因素的进化的产物，传染病患者施加了有效的选择压力。当今的一些主要免疫介导的疾病与进化以应对病原体的基因有关。可以通过了解病原体如何调节和篡夺免疫系统的新型治疗策略和新药物，也可以通过鉴定病原体的功能分子来开发。实际上，新一代病原体衍生的免疫调节分子现在正在临床试验中。在这次会议上，领先的专家将介绍使用病原体作为新疗法源源的现状。该论坛将是行业与学者互动以制定新颖的药物发现策略的机会。这次会议将汇集跨学科的科学家来交换和分享思想，从而促进致力于为未来创造新药策略的合作。这次会议与Keystone研讨会会议的共同座位将大大提高跨学科互动的机会。公共卫生相关性：药物发现技术的进步提高了人们的期望，即全球药物开发行业将为各种疾病，尤其是炎症性疾病提供“魔术子弹”或“神奇药物”。实际上，由于全世界在多种疾病（例如哮喘和炎症性肠病）的发生率增加，因此缺乏新的治疗方法是从管道到诊所的发展较少，因此缺乏新的治疗方法。 Keystone研讨会会议上关于虫子的药物：明天的抗炎药将研究从病原体中发现新型药物的越来越多的机会，或者是“臭虫中的药物”方法。